Lilly's Verzenio shows up Ibrance, hitting its goal in early breast cancer. Will Verzenio’s in-class competitors, Pfizer’s Ibrance and Novartis’ Kisqali, look to enter the high-risk early #breastcancer patient market next? #bcsm $LLY $PFE
https://t.co/L1m6oMqSPA https://t.co/1qnp3Y7Til